1.64
-0.01 (-0.61%)
| Penutupan Terdahulu | 1.65 |
| Jumlah Dagangan | 2,620 |
| Harga / Buku (P/B) | 2.22 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -1.59 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 78.99% |
| Nisbah Semasa (MRQ) | 5.66 |
| Aliran Tunai Operasi (OCF TTM) | -21.31 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -12.63 M |
| Pulangan Atas Aset (ROA TTM) | -59.39% |
| Pulangan Atas Ekuiti (ROE TTM) | -134.15% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | CalciMedica, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | -1.50 |
|
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 16.45% |
| % Dimiliki oleh Institusi | 58.12% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| L1 Global Manager Pty Ltd | 30 Jun 2026 | 49,794 |
| 180 Wealth Advisors, Llc | 30 Jun 2026 | 16,680 |
| Meritage Portfolio Management | 31 Dec 2025 | 12,308 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |